There are an estimated one million peptides in the human body. We have identified and studied a few hundred. What those few hundred have already shown us is remarkable enough to make the question of what the rest might do one of the most compelling in all of science.
A peptide is a short chain of amino acids — the same building blocks that make proteins, but fewer of them, linked in a specific sequence. Where proteins might contain hundreds or thousands of amino acids folded into complex three-dimensional structures, peptides are typically between 2 and 50 amino acids long. Small enough to be highly mobile, precise enough to carry specific instructions.
The human body uses peptides as signalling molecules — chemical messages passed between cells, organs and systems. They tell cells to divide or stop dividing. They modulate inflammation. They regulate hunger and satiety. They govern sleep cycles, stress responses, immune function, tissue repair, hormone production and dozens of other processes so fundamental that without them, none of the more complex biology we associate with being alive would function.
Insulin is a peptide. So is oxytocin — the molecule involved in social bonding and trust. So is the hormone that triggers ovulation. So are the endorphins released during exercise. So is the compound your body produces to regulate blood pressure. Peptides are not exotic or fringe — they are the operating system.
The human proteome — the complete set of proteins the body can produce — is estimated at around 20,000 proteins. The human peptidome — the complete set of peptides — is estimated at over one million distinct molecules. Most have never been studied. Most don't yet have names.
Every tissue, every fluid, every organ produces its own specific peptide profile. Blood, cerebrospinal fluid, saliva, urine, breast milk — each contains thousands of peptides performing functions we are only beginning to catalogue.
The question of why the body reduces its own peptide production as we age does not yet have a complete answer. What we know is that it happens — measurably, consistently, across species — and that the consequences are significant.
Growth hormone secretion peaks in adolescence and declines by roughly 14% per decade thereafter. IGF-1, the primary downstream mediator of GH's tissue effects, follows the same curve. Thymosin production — the family of peptides critical to immune function and thymic activity — declines as the thymus gland atrophies, a process that begins in the early twenties and continues throughout life. Telomere-protective peptides, collagen-regulating peptides, peptides involved in mitochondrial energy production — all follow similar declining trajectories.
"Whether this decline is the cause of ageing or a consequence of it is one of the genuinely open questions in longevity science. The honest answer is probably both — a feedback loop that is easier to observe than to interrupt."
Several hypotheses have been proposed. The evolutionary disposability theory suggests the body's repair and maintenance systems are calibrated for reproductive success, not longevity — once reproduction is no longer the priority, maintenance signals weaken. The epigenetic clock theory suggests that gene expression shifts gradually over time, reducing transcription of certain signalling peptides as cellular programming drifts from its original state. The accumulated damage theory suggests that the machinery responsible for peptide production degrades over time under oxidative stress, inflammation and replication error.
The honest answer is probably all three, operating simultaneously, in a feedback loop that is easier to observe than to interrupt.
What is agreed upon is this: many of the physical changes we associate with ageing — reduced muscle mass, slower wound healing, impaired immune response, declining cognitive clarity, increased inflammation, altered metabolism — correlate strongly with declines in specific peptide signalling. Whether restoring those signals restores those functions is the question that drives the research.
The peptides we have studied most thoroughly — BPC-157, TB-500, the GH secretagogues, GLP-1 agonists, Epitalon, Thymosin Alpha-1 — have collectively demonstrated something important: that exogenous peptide administration can produce measurable biological effects that align with the effects of the body's own declining production.
BPC-157, isolated from human gastric juice, accelerates tendon healing in animal models by margins that have been consistently replicated across dozens of studies. It activates VEGF pathways, promotes angiogenesis, and modulates nitric oxide in ways that reduce inflammation and accelerate tissue repair. The mechanism is understood well enough that researchers can explain precisely why it works — not just observe that it does.
Epitalon — a tetrapeptide derived from the pineal gland's epithalamin — has shown telomere elongation effects in multiple cell studies and one notable human study by Dr Vladimir Khavinson in Russia, which documented extended lifespan and reduced cancer incidence in a cohort of elderly patients over a 12-year follow-up period. It remains one of the most striking pieces of human longevity data in the peptide literature, and one of the least cited in Western research.
The GLP-1 agonists — semaglutide, tirzepatide, retatrutide — have moved from research curiosities to blockbuster medicines within a decade. They demonstrate what is possible when a peptide mechanism is well understood and well funded: a class of compounds that mimics the body's own satiety signalling has produced weight reduction results that no previous pharmaceutical intervention achieved.
GLP-1 (glucagon-like peptide-1) is a peptide the body produces naturally in response to food. It was identified in the 1980s. Its role in satiety signalling was understood by the 1990s. The first GLP-1 receptor agonist drug (exenatide) reached clinical approval in 2005. Semaglutide — now prescribed to tens of millions — followed 12 years later.
The timeline from basic peptide science to clinical medicine is long. What this means is that the peptide mechanisms being studied in basic science today — telomere extension, senolytic clearance, mitochondrial regeneration — are most likely 10 to 20 years from becoming mainstream medicine. They are not fringe. They are early.
This is the question that sits at the edge of what can be stated with scientific confidence and what can only be reasoned about carefully. But it is worth reasoning about carefully, because the stakes are significant.
If the body's decline is substantially driven by declining peptide signalling — and there is meaningful evidence that this is at least partly true — then the logical question is what happens if those signals are maintained. Not necessarily amplified or pushed beyond natural ranges, but maintained at levels the body itself sustained during its peak functional years.
The gap between what peptide science currently demonstrates and what it might eventually deliver is large — and that gap is partly scientific, partly economic, and partly a function of time.
The scientific challenge is that most peptide research exists at the animal study stage. Rodents heal faster on BPC-157. Mice with Alzheimer's models improve on certain peptides. Cells in a dish behave as predicted. But the translation from mouse to human is consistently harder than it looks, and the longevity research faces an additional problem: the most important outcomes — does this extend healthy human lifespan? — take decades to measure properly.
The economic challenge is that peptides cannot be easily patented in their natural form. A pharmaceutical company cannot spend £500 million developing a clinical trial for a compound anyone can synthesise. This means the peptide research that most needs funding — large human trials over long time periods — is precisely the research that market incentives make least attractive. The GLP-1 agonists succeeded commercially because they were modified enough to be patentable. Most recovery and longevity peptides are not.
"We are in the position of having discovered that the body communicates in a language we cannot yet fully read, with a vocabulary of perhaps a million words, of which we have learned a few hundred. The ones we have learned are already capable of extraordinary things."
What this leaves us with is a field of genuine promise operating largely outside mainstream medicine — because mainstream medicine moves at the speed of clinical trial completion and regulatory approval, and those timelines are measured in decades. The people using peptides today are, in effect, self-experimenting at the frontier of what the science suggests but cannot yet prove.
That is not necessarily wrong. It is, in fact, how most of medicine has worked throughout history. The question is whether the information available to guide those decisions is accurate, honest and appropriately cautious. That is what Pep IQ exists to provide.
This is speculative. It is worth being clear about that. But it is informed speculation, grounded in what the peptides we have already found can do.
If the roughly one hundred peptides in active research can already demonstrate accelerated tissue repair, immune reactivation, metabolic correction, GH axis support, telomere maintenance and senescent cell clearance — what might the remaining 993,000 do?
The honest answer is that we do not know. But the pattern established by the ones we have found suggests that the body's peptide signalling system is vastly more sophisticated than any therapeutic approach we have yet developed. Every peptide discovered so far has revealed a new mechanism, a new target, a new biological process that nobody had previously understood could be addressed at the molecular level.
The most transformative discoveries in peptide science have not come from searching for a specific effect. They have come from finding a peptide, studying it carefully, and discovering that it does something nobody expected. BPC-157 was found in gastric juice — a digestive peptide that turned out to accelerate systemic tissue repair. GLP-1 was a gut hormone that turned out to be the most effective obesity treatment ever discovered. The unexpected has been the rule, not the exception.
If even a fraction of the undiscovered peptidome contains molecules with comparable specificity and potency to those already found, the implications are difficult to overstate. Not because any single peptide will be a cure for ageing — the biology is too complex for that — but because the cumulative understanding of how the body signals repair, maintenance and regeneration may eventually provide enough of the picture to meaningfully intervene in the processes that cause it to decline.
Whether that constitutes extending life is a question that depends partly on the science and partly on what we mean by the word. Extending a period of health — a period of functional, cognitively intact, physically capable life — is already within reach of what current peptide protocols in clinical use can support. Extending the biological limit of human lifespan is a different and harder question, and one that will not be answered for decades, if ever.
What is worth stating clearly is this: the research is real, the mechanisms are understood, and the compounds that have been found so far have demonstrated enough to make the question of what the rest might do genuinely important. This is not wishful thinking or supplement marketing. It is a recognition that we are at the beginning of something the scale of which we cannot yet see clearly — and that being informed about what is currently known is a reasonable and considered response to that situation.
71 compound entries, 20 protocol references. Updated as research evolves. Everything currently understood about the compounds being studied and used — in one place.
Subscribe from £4.99/mo →